WO2015050471A1 - Composés carbazole et leurs méthodes d'utilisation - Google Patents

Composés carbazole et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2015050471A1
WO2015050471A1 PCT/RU2013/000866 RU2013000866W WO2015050471A1 WO 2015050471 A1 WO2015050471 A1 WO 2015050471A1 RU 2013000866 W RU2013000866 W RU 2013000866W WO 2015050471 A1 WO2015050471 A1 WO 2015050471A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
substituted
mmol
group
unsubstituted
Prior art date
Application number
PCT/RU2013/000866
Other languages
English (en)
Inventor
Katerina Gurova
Elena Borisovna RYDKINA
Warren Wade
Original Assignee
Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs" filed Critical Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs"
Priority to PCT/RU2013/000866 priority Critical patent/WO2015050471A1/fr
Publication of WO2015050471A1 publication Critical patent/WO2015050471A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present disclosure provides carbazole compounds and carbazole- like compounds.
  • the compounds can be used to treat microbial infections (e.g., fungal infections) and selectively kill cancer cells.
  • heterocyclic compounds having the following structure (I):
  • R at each occurrence is independently absent, a hydrogen atom, a fluorine atom, a chlorine atom, a hydroxyl group, a cyano group, a substituted or unsubstituted C
  • R 3 is selected from the group consisting of a hydrogen atom, a substituted or unsubstituted Ci-C 6 alkyl group, cycloalkyl group, heterocycloalkyl group, or taken together with R 4 and the nitrogen atom to which they are attached form a four to eight membered substituted or unsubstituted heterocyclic ring;
  • R 4 is selected from the group consisting of a hydrogen atom, a substituted or unsubstituted C
  • Y is a carbon or nitrogen atom;
  • C is
  • alkyl group refers to branched or unbranched hydrocarbons.
  • alkyl groups include methyl groups, ethyl groups, propyl groups, butyl groups, isopropyl groups, tert-butyl groups, and the like.
  • the alkyl group can be a d to C 6 alkyl group including all integer numbers of carbons and ranges of numbers of carbons therebetween.
  • Alkyl groups can be substituted with various other functional groups.
  • the alkyl groups can be substituted with groups such as, for example, amines (acyclic and cyclic), alcohol groups, ether groups, and halogen atoms.
  • halogen atom refers to a fluorine, chlorine, bromine, or iodine atom.
  • alkoxy groups can be substituted with various other functional groups.
  • the alkyl groups can be unsubstituted or substituted with groups such as, for example, halogen atoms.
  • cycloalkyl group refers to a to a saturated or partially unsaturated carbocyclic group (not aromatic) of from 3 carbons to 1 1 carbons having a single cyclic ring or multiple condensed rings.
  • the cycloalkyl groups can be cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclohexene, cycloheptane, cycloheptene, bicyclo[2.1.
  • Cycloalkyl also includes carbocyclic groups to which is fused an aryl or heteroaryl ring, for example indane and tetrahydronaphthalene.
  • the cycloalkyl groups can be unsubstituted or substituted with groups such as, for example, alkyl groups, carbonyl groups, ether groups, or halogen groups.
  • heterocycloalkyl group refers to a saturated or partially unsaturated group having a single cyclic ring or multiple condensed rings having from 2 to 1 1 carbon atoms and 1 to 5 heteroatoms, selected from nitrogen, oxygen, sulfur, and combinations thereof.
  • the heterocycloalkyl groups can be, for example, dihydrofuran, tetrahydrofuran, pyrrolidine, dihydropyran, tetrahydropyran, 1 ,3 dioxane, 1 ,4- dioxane, dihydropyridinone, piperidine, piperazine, morpholine, thiomorpholine, urazole, 2-aza- bicyclo[2.2.2]oct-5-ane-3-one, and the like.
  • Heteroccycloalkyl also includes heterocyclic groups to which is fused an aryl or heteroaryl ring, for example tetrahydroisoquinoline or indoline.
  • the heterocycloalkyl groups can be unsubstituted or substituted with groups such as, for example, alkyl groups, carbonyl groups, or halogen atoms.
  • heterocycle refers to a cyclic compound having a ring where at least one or more of the atoms forming the ring is a heteroatom (e.g., oxygen, nitrogen, sulfur, etc.).
  • the heterocyclic ring can be aromatic or nonaromatic, and include compounds that are saturated, partially unsaturated, and fully unsaturated.
  • Examples of such groups include azetidine, pyrrolidine, piperdine, azepane, azocane, dihydropyrdinone, dihydropyridazinone, dihydrooxepinone, dihydroazepinone, pyrazolone, pyrrolone, isoxazolone, pyranone, dihydrodiazepineone, furan, thiophene, oxazole, isoxazole, thiazole, oxadiazole, thiadiazole, triazole, tetrazole, oxazoline, lactam, lactone, dihydrofuran, tetrahydrofuran, furanone, oxazolone, pyridinone, pyrimidinone, dihydropyridazine, pyranone, oxazinone, and the like.
  • the heterocyclic ring can be a 4, 5, 6, 7, or 8 membered ring containing a number of carbon atoms ranging between 1 and 7 and a number of heteroatoms ranging between 1 and 7.
  • the heterocyclic ring can be unsubstituted or substituted with groups such as, for example, alkyl groups, carbonyl groups, or halogen atoms.
  • the carbocyclic ring can be aromatic or nonaromatic, and include compounds that are saturated and partially unsaturated, and fully unsaturated. Examples of such groups include cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexanone, cyclohexenone, cyclopentanone, cyclopentanol, cycloheptenone, indane, indanone, phenyl, naphthyl and the like.
  • the carbocyclic ring is a C 5 to C 7 carbocyclic ring, including all integer numbers of carbons and ranges of numbers of carbons therebetween.
  • the carbocyclic ring can be unsubstituted or substituted with groups such as, for example, alkyl groups, carbonyl groups, or halogen atoms.
  • heterocyclic compounds having the following structure (II):
  • heterocyclic compounds having the following structure (III):
  • R 6 is independently a hydrogen atom or a substituted or unsubstituted C 1 -C3 alkyl group and where R 2 , R 3 , R 4 , C, D, E, and Y are as defined herein.
  • the structure R 3 is selected from the group consisting of
  • R 3 is -CH(CH 3 ) 2 , -CH 2 CH 3 , cyclopropyl, or cyclobutyl;
  • R 4 is -a hydrogen atom, -CH 3 , -CH 2 CH 3 or taken together with R 3 and the nitrogen to which they are attached form the following structures: or
  • R 5 is as defined herein.
  • At least one Y is a nitrogen atom.
  • heterocyclic compounds having the following structure (IV):
  • heterocyclic compounds having the following structure (V):
  • R 2 , R 3 , R 4 , Y, F, G, J, and K are as defined herein.
  • heterocyclic compounds having the following structure (VI):
  • the compound of the present disclosure is selected from the following structures:
  • the disclosure provides a method of treating in an individual diagnosed with or suspected of having a microbial, protozoan, or viral infection comprising administering to the individual a therapeutically effective amount of a compound as described herein.
  • each Z' independently is a halogen, a trifluoromethanesulfonate, a trialkyltin, a boronic acid, or boronic ester as long as one coupling partner Z' is a halogen and the other coupling partner Z' is not a halogen.
  • Ring A, ring B, R 2 , R 3 , R 4 , Y, C, D, and E are as defined herein.
  • suitable reaction conditions for cross coupling, the Cadogan reaction, alkylation, and other functional group transformations are within the purview of one having skill in the art.
  • heterocycles of the present disclosure it may be necessary to form the heterocycles of the present disclosure by well-established condensation reactions.
  • To assemble the coupling partners or further functionalize the aromatic components of the present disclosure it may be necessary to use of electrophilic aromatic substitution reactions, nucleophilic aromatic substitution reactions, anion chemistry, and the like.
  • electrophilic aromatic substitution reactions nucleophilic aromatic substitution reactions, anion chemistry, and the like.
  • Other oxidation state and functional groups manipulations are within the purview of one having skill in the art.
  • the present disclosure provides a composition comprising at least one compound of the disclosure.
  • Compositions comprising at least one compound of the disclosure include, for example, pharmaceutical preparations.
  • the present disclosure includes all possible stereoisomers and geometric isomers of a compound having the structure (I) to (VI).
  • the present disclosure includes both racemic compounds and optically active isomers.
  • a compound having the structure (I) to (VI) is desired as a single enantiomer, it can be obtained either by resolution of the final product or by stereospecific synthesis from either isomerically pure starting material or use of a chiral auxiliary reagent, for example, see Z.
  • Prodrugs of a compound having the structure (I) to (VI) also can be used as the compound in a method of the present disclosure. It is well established that a prodrug approach, wherein a compound is derivatized into a form suitable for formulation and/or administration, then released as a drug in vivo, has been successfully employed to transiently (e.g., bioreversibly) alter the physicochemical properties of the compound (see, H. Bundgaard, Ed., “Design of Prodrugs,” Elsevier, Amsterdam, (1985); R.B. Silverman, "The Organic Chemistry of Drug Design and Drug Action,” Academic Press, San Diego, chapter 8, ( 1992); K.M. Hillgren et al., Med. Res. Rev., 15, 83 (1995)).
  • Compounds of the present disclosure can contain one or more functional groups.
  • Suitable prodrugs include, for example, acid derivatives, such as amides and esters. It also is appreciated by those skilled in the art that N-oxides can be used as a prodrug.
  • compositions of the disclosure can exist as salts.
  • Pharmaceutically acceptable salts of the compounds of the disclosure generally are preferred in the methods of the disclosure.
  • the term "pharmaceutically acceptable salts” refers to salts or zwitterionic forms of a compound having the structure (I) to (VI). Salts of compounds having the structure (I) to (VI) can be prepared during the final isolation and purification of the compounds or separately by reacting the compound with an acid having a suitable cation.
  • the pharmaceutically acceptable salts of a compound having the structure (I) to (VI) are acid addition salts formed with pharmaceutically acceptable acids.
  • acids which can be employed to form pharmaceutically acceptable salts include inorganic acids such as nitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
  • Nonlimiting examples of salts of compounds of the disclosure include, but are not limited to, the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, 2-hydroxyethansulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerolphsphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, mesitylenesulfonate, naphthylenesulfonate, nicotinate, 2- naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3- phenylproprionate, picrate
  • any reference to compounds of the present disclosure appearing herein is intended to include a compound having the structure (I) to (VI) as well as pharmaceutically acceptable salts, hydrates, or prodrugs thereof.
  • a compound having the structure (I) to (VI) also can be conjugated or linked to auxiliary moieties that promote a beneficial property of the compound in a method of therapeutic use.
  • auxiliary moieties can enhance delivery of the compounds to a particular anatomical site or region of interest (e.g., a tumor), enable sustained therapeutic concentrations of the compounds in target cells, alter pharmacokinetic and pharmacodynamics properties of the compounds, and/or improve the therapeutic index or safety profile of the compounds.
  • Suitable auxiliary moieties include, for example, amino acids, oligopeptides, or polypeptides, e.g., antibodies such as monoclonal antibodies and other engineered antibodies; and natural or synthetic ligands to receptors in target cells or tissues.
  • compositions comprising at least one compound of the disclosure.
  • compositions comprising at least one compound of the disclosure include, for example, pharmaceutical preparations.
  • terapéuticaally effective amount of a compound of the disclosure refers to an amount of an agent which is effective, upon single or multiple dose administration to the patient, in inhibiting cell proliferation and/or symptoms of a cell proliferative disorder, or in prolonging the survivability of the patient with such a cell proliferative disorder beyond that expected in the absence of such treatment.
  • the exact amount desired or required will vary depending on the particular compound or composition used, its mode of administration, and the like. Appropriate effective amount can be determined by one of ordinary skill in the art informed by the instant disclosure using only routine experimentation.
  • treatment also includes relapse prophylaxis or phase prophylaxis, as well as the treatment of acute or chronic signs, symptoms and/or malfunctions.
  • the treatment can be orientated symptomatica! ly, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy.
  • compositions comprising a compound of the disclosure and a pharmaceutical agent can be prepared at a patient's bedside, or by a pharmaceutical manufacture.
  • the compositions can be provided in any suitable container, such as a sealed sterile vial or ampoule, and may be further packaged to include instruction documents for use by a pharmacist, physician or other health care provider.
  • the compositions can be provided as a liquid, or as a lyophilized or powder form that can be reconstituted if necessary when ready for use.
  • the compositions can be provided in combination with any suitable delivery form or vehicle, examples of which include, for example, liquids, caplets, capsules, tablets, inhalants or aerosol, etc.
  • the delivery devices may comprise components that facilitate release of the pharmaceutical agents over certain time periods and/or intervals, and can include compositions that enhance delivery of the pharmaceuticals, such as nanoparticle, microsphere or liposome formulations, a variety of which are known in the art and are commercially available. Further, each composition described herein can comprise one or more pharmaceutical agents.
  • the compositions described herein can include one or more standard pharmaceutically acceptable carriers. Some examples of pharmaceutically acceptable carriers can be found in: Remington: The Science and Practice of Pharmacy (2005) 21 st Edition, Philadelphia, PA. Lippincott Williams & Wilkins.
  • compositions of the disclosure can be administered in any manner including, but not limited to, orally, parenterally, sublingually, transdermal ly, rectally, transmucosally, topically, via inhalation, via buccal administration, or combinations thereof.
  • Parenteral administration includes, but is not limited to, intravenous, intraarterial, intracranial, intradermal, subcutaneous, intraperitoneal, subcutaneous, intramuscular, intrathecal, and intraarticular.
  • the carbazole compound also can be administered in the form of an implant, which allows a slow release of the compound, as well as a slow controlled i.v. infusion.
  • the dose of the composition comprising a compound of the disclosure and a pharmaceutical agent generally depends upon the needs of the individual to whom the composition of the disclosure is to be administered. These factors include, for example, the weight, age, sex, medical history, and nature and stage of the disease for which a therapeutic or prophylactic effect is desired.
  • the compositions can be used in conjunction with any other conventional treatment modality designed to improve the disorder for which a desired therapeutic or prophylactic effect is intended, non-limiting examples of which include surgical interventions and radiation therapies.
  • the compositions can be administered once, or over a series of administrations at various intervals determined using ordinary skill in the art, and given the benefit of the present disclosure.
  • compositions of the disclosure can comprise more than one pharmaceutical agent.
  • a first composition comprising a compound of the disclosure and a first pharmaceutical agent can be separately prepared from a composition which comprises the same compound of the disclosure and a second pharmaceutical agent, and such preparations can be mixed to provide a two-pronged (or more) approach to achieving the desired prophylaxis or therapy in an individual.
  • compositions of the disclosure can be prepared using mixed preparations of any of the compounds disclosed herein.
  • a compound having the structure (I) to (VI) are useful in the treatment of a variety of conditions and diseases.
  • the present disclosure concerns the use of a compound having the structure (I) to (VI), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the treatment of such conditions and diseases.
  • the compounds of the present disclosure can be therapeutically administered as the neat chemical, but it is preferred to administer a compound having the structure (I) to (VI) as a pharmaceutical composition or formulation.
  • a pharmaceutical composition comprising a compound having the structure (I) to (VI) together with a pharmaceutically acceptable diluent or carrier therefor.
  • a process of preparing a pharmaceutical composition comprising admixing a compound having the structure (I) to (VI) with a pharmaceutically acceptable diluent or carrier therefor.
  • the present disclosure further provides pharmaceutical formulations comprising a compound having the structure (I) to (VI), or a pharmaceutically acceptable salt, prodrug, or hydrate thereof, together with one or more pharmaceutically acceptable carriers and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carriers are "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Examples of pharmaceutically-acceptable carrier include pharmaceutical ly- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body.
  • pharmaceutically-acceptable carrier include pharmaceutical ly- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body.
  • materials which can serve as pharmaceutically-acceptable carriers include: (1 ) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; ( 10) glycols, such as propylene glycol; ( 1 1 ) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; ( 13) agar; (14) buffering agents, such as magnesium, magnesium
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: (1 ) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT
  • the pharmaceutically-acceptable formulation is such that it provides sustained delivery of a compound having the structure (I) to (VI) to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
  • these pharmaceutical compositions are suitable for topical or oral administration to a subject.
  • the pharmaceutical compositions of the present disclosure may be specially formulated for administration in solid or liquid form, including those adapted for the following: ( 1 ) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles.
  • compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary P
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of a compound having the structure (1) to (VI) which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, more preferably from about 10 per cent to about 30 per cent.
  • Methods of preparing these compositions include the step of bringing into association a compound having the structure (I) to (VI) with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a compound having the structure (I) to (VI) with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • compositions of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound having the structure (I) to (VI) as an active ingredient.
  • a compound having the structure (I) to (VI) may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically-acceptab!e carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1 ) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) we
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present disclosure may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol
  • the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
  • the composition may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • compositions of the disclosure for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a compound having the structure (I) to (VI) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
  • compositions of the present disclosure which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of a compound having the structure (I) to (VI) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • a compound having a structure (I) to (VI) may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • the ointments, pastes, creams and gels may contain, in addition to a compound having the structure (I) to (VI), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to a compound having a structure (I) to (VI), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically-acceptable carriers and stabilizers.
  • the carriers and stabilizers vary with the requirements of the particular a compound having the structure (I) to (VI), but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
  • Aerosols generally are prepared from isotonic solutions.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound having the structure (I) to (VI) to the body.
  • dosage forms can be made by dissolving or dispersing the agent in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the active ingredient across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active ingredient in a polymer matrix or gel.
  • Ophthalmic formulations are also contemplated as being within the scope of the disclosure.
  • compositions of the disclosure suitable for parenteral administration comprise a compound having the structure (I) to (VI) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and
  • Injectable depot forms are made by forming microencapsule matrices of a compound having the structure (I) to (VI) in biodegradable polymers such as polylactide- polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
  • a compounds having a structure (I) to (VI) are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically-acceptable carrier.
  • a compound having the structure (I) to (VI), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into pharmaceutical ly-acceptable dosage forms by conventional methods known to those of skill in the art.
  • the pharmaceutical preparations may be given by forms suitable for each administration route.
  • these preparations are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories.
  • Oral administration is preferred.
  • the injection can be bolus or can be continuous infusion.
  • a compound having the structure (I) to (VI) of the present disclosure can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally affect its ability to perform its intended function.
  • a compound having the structure (I) to (VI) may be administered alone, or in conjunction with either another agent as described above or with a pharmaceutically-acceptable carrier, or both.
  • a compound having the structure (I) to (VI) may be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent.
  • a compound having the structure (I) to (VI) can also be administered in a pro-drug form which is converted into its active metabolite, or more active metabolite in vivo.
  • the methods of the disclosure include administering to a subject a therapeutically effective amount of a compound having the structure (I) to (VI) in combination with another pharmaceutically active ingredient.
  • pharmaceutically active ingredients known to treat cell proliferative disorders, e.g., anticancer agent, antiproliferative agent, chemotherapeutic.
  • Other pharmaceutically active ingredients that may be used can be found in Harrison's Principles of Internal Medicine, Thirteenth Edition, Eds. T.R. Harrison et al. McGraw-Hill N.Y., NY; and the Physicians Desk Reference 50th Edition 1997, Oradell New Jersey, Medical Economics Co., the complete contents of which are expressly incorporated herein by reference.
  • a compound having the structure (I) to (VI) and the pharmaceutically active ingredient may be administered to the subject in the same pharmaceutical composition or in different pharmaceutical compositions (at the same time or at different times).
  • Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method). In other methods, the subject is prescreened or identified as in need of such treatment by assessment for a relevant marker or indicator of suitability for such treatment.
  • a compound having the structure (I) to (VI) determined to be effective for the prevention or treatment of cell proliferative disorders in animals may also be useful in treatment of tumors in humans.
  • animals e.g., dogs, chickens, and rodents
  • Those skilled in the art of treating tumors in humans will know, based upon the data obtained in animal studies, the dosage and route of administration of a compound having the structure (I) to (VI) to humans. In general, the dosage and route of administration in humans is expected to be similar to that in animals.
  • the subject may have a cell proliferative disorder, may be at risk of developing a cell proliferative disorder, or may need prophylactic treatment prior to anticipated or unanticipated exposure to a condition(s) capable of increasing susceptibility to a cell proliferative disorder, e.g., exposure to carcinogens or to ionizing radiation.
  • a condition(s) capable of increasing susceptibility to a cell proliferative disorder e.g., exposure to carcinogens or to ionizing radiation.
  • a method of monitoring the progress of a subject being treated with a compound having the structure (I) to (VI) includes determining the pre-treatment status (e.g., size, growth rate, or invasiveness of a tumor) of the cell proliferative disorder, administering a therapeutically effective amount of a compound having the structure (I) to (VI) to the subject, and determining the status (e.g., size, growth rate, or invasiveness of a tumor) of the cell proliferative disorder after an initial period of treatment with a compound having the structure (I) to (VI), wherein the modulation of the status indicates efficacy of the treatment.
  • the pre-treatment status e.g., size, growth rate, or invasiveness of a tumor
  • the disclosure provides a packaged composition including a therapeutically effective amount of a compound having the structure (I) to (VI) and a pharmaceutically acceptable carrier or diluent.
  • the composition may be formulated for treating a subject suffering from or susceptible to a cell proliferative disorder, and packaged with instructions to treat a subject suffering from or susceptible to a cell proliferative disorder.
  • the disclosure provides a kit for treating a cell proliferative disorder, microbial disease, e.g., fungal disease; protozoan disease; or viral disease in a subject is provided and includes a compound having the structure (I) to (VI), pharmaceutically acceptable esters, salts, and prodrugs thereof, and instructions for use.
  • the disclosure provides kits for inhibiting cell proliferation, assessing the efficacy of an anti-cell proliferative treatment in a subject, monitoring the progress of a subject being treated with a cell proliferation inhibitor, selecting a subject with a cell proliferative disorder for treatment with cell proliferation inhibitor, and/or treating a subject suffering from or susceptible to cancer.
  • the disclosure provides: a kit for treating a cell proliferative disorder, microbial disease, e.g., fungal disease; protozoan disease; or viral disease in a subject, the kit comprising a compound having the structure (I) to (VI).
  • microbial disease e.g., fungal disease; protozoan disease; or viral disease
  • kit comprising a compound having the structure (I) to (VI).
  • a compound having the structure (I) to (VI), or a pharmaceutically acceptable salt or prodrug is administered as a suitably acceptable formulation in accordance with normal veterinary practice.
  • the veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.
  • Animals treatable by the present compounds and methods include, but are not limited to, pets, livestock, show animals, and zoo specimens.
  • a present carbazole compound When administered in combination with other therapeutics, a present carbazole compound may be administered at relatively lower dosages. In addition, the use of targeting agents may allow the necessary dosage to be relatively low. Certain compounds may be administered at relatively high dosages due to factors including, but not limited to, low toxicity and high clearance.
  • a compound having the structure (I) to (VI) can be administered alone, but generally is administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • Pharmaceutical compositions for use in accordance with the present disclosure can be formulated in a conventional manner using one or more physiologically acceptable carrier comprising excipients and auxiliaries that facilitate processing of a compound having the structure (I) to (VI) into pharmaceutical preparations.
  • the present carbazole compounds can be administered simultaneously or metronomically with other anti-cancer treatments, such as chemotherapy and/or radiation therapy.
  • anti-cancer treatments such as chemotherapy and/or radiation therapy.
  • the term “simultaneous” or “simultaneously” means that the other anti-cancer treatment and the carbazole compound are administered within 6 hours, 3 hours or less, of each other.
  • the term “metronomically” means the administration of the other anti-cancer treatments at times different from the anti-cancer treatments and at a certain frequency relative to repeat administration and/or the anti-cancer treatment regimen.
  • the carbazole compounds of the present disclosure can be used to treat a variety of diseases and conditions.
  • compounds of the present disclosure can be used in combination with radiation and/or a chemotherapeutic agent in the treatment of cancers.
  • the carbazole compounds can be used to enhance treatment of tumors that are customarily treated with an antimetabolite, e.g., methotrexate or 5-fluorouracil (5-FU).
  • an antimetabolite e.g., methotrexate or 5-fluorouracil (5-FU).
  • carbazole compounds of the present disclosure can result in partial or complete regression of cancer cells, i.e., the partial or complete disappearance of such cells from the cell population.
  • a method of the disclosure can be used to slow the rate of tumor growth, decrease the size or number of tumors, or to induce partial or complete tumor regression.
  • a compound having the structure (I) to (VI) can be used for treating a disease or condition in vivo by administration to an individual in need thereof.
  • the disease or condition can be a cancer.
  • a variety of cancers can be treated including, but not limited to: carcinomas, including bladder (including accelerated and metastic bladder cancer), breast, colon (including colorectal cancer), kidney, liver, lung (including small and non-small cell lung cancer and lung adenocarcinoma), ovary, prostate, testes, genitourinary tract, lymphatic system, rectum, larynx, pancreas (including exocrine pancreatic carcinoma), esophagus, stomach, gall bladder, cervix, thyroid, renal, and skin (including squamous cell carcinoma); hematopoietic tumors oflymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, 8- celllymphoma, T-cell lymphoma, Ho
  • One method of the present disclosure comprises administration of a therapeutically effective amount of a present carbazole compound in combination with a chemotherapeutic agent that can effect single- or double-strand DNA breaks or that can block DNA replication or cell proliferation.
  • a method of the present disclosure comprises administration of a therapeutically effective amount of at least one present carbazole compound in combination with therapies that include use of an antibody, e.g., herceptin, that has activity in inhibiting the proliferation of cancer cells.
  • cancers for example, colorectal cancers, head and neck cancers, pancreatic cancers, breast cancers, gastric cancers, bladder cancers, vulvar cancers, leukemias, lymphomas, melanomas, renal cell carcinomas, ovarian cancers, brain tumors, osteosarcomas, and lung carcinomas, are susceptible to enhanced treatment by administration of a present carbazole in combination with a chemotherapeutic agent or an antibody.
  • Cancers treatable by the present disclosure also include solid tumors, i.e., carcinomas and sarcomas.
  • Carcinomas include malignant neoplasms derived from epithelial cells which infiltrate (i.e., invade) surrounding tissues and give rise to metastases.
  • Adenocarcinomas are carcinomas derived from glandular tissue, or from tissues that form recognizable glandular structures.
  • Another broad category of cancers includes sarcomas, which are tumors whose cells are embedded in a fibrillar or homogeneous substance, like embryonic connective tissue.
  • the present disclosure also enables treatment of cancers of the myeloid or lymphoid systems, including leukemias, lymphomas, and other cancers that typically are not present as a tumor mass, but are distributed in the vascular or lymphoreticular systems.
  • Additional forms of cancer treatable by the present carbazole compounds include, for example, adult and pediatric oncology, growth of solid tumors/malignancies, myxoid and round cell carcinoma, locally advanced tumors, metastatic cancer, human soft tissue sarcomas, including Ewing's sarcoma, cancer metastases, including lymphatic metastases, squamous cell carcinoma, particularly of the head and neck, esophageal squamous cell carcinoma, oral carcinoma, blood cell malignancies, including multiple myeloma, leukemias, including acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, and hairy cell leukemia, effusion lymphomas (body cavity based lymphomas), thymic lymphoma lung cancer (including small cell carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma
  • a compound having the structure (I) to (VI) exhibit antimicrobial activity, e.g., fungal infection; antiprotozoan activity; and antiviral activity.
  • the fungal infection is from the pathogenic fungi from C. albicans, C. glabrata, A. fumigatus, or a combination thereof.
  • the compounds of the disclosure are those in which show ⁇ 40% growth inhibition at 20 ⁇ , >10 ⁇ , 5-10 ⁇ , or ⁇ 5 ⁇ MIC for 95% inhibition of growth towards three different fungal species (i.e., C. albicans, C. glabrata, and A.fumigatus).
  • the present disclosure can be applied to cell populations ex vivo.
  • the present carbazole compounds can be used ex vivo to determine the optimal schedule and/or dosing of administration of the present carbazole compound for a given indication, cell type, patient, and other parameter. Information gleaned from such use can be used for experimental purposes or in the clinic to set protocol for in vivo treatment. Other ex vivo uses for which the disclosure is suited are apparent to those skilled in the art.
  • a present carbazole compound also can be administered in combination with radiation.
  • Diseases that are treatable with electromagnetic radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells.
  • Electromagnetic radiation treatment of other diseases not listed herein also is contemplated by the present disclosure.
  • Preferred embodiments of the present disclosure employ the electromagnetic radiation of: gamma-radiation (10-20 to 10- 13 m), X-ray radiation (10-12 to 10-9 m), ultraviolet light (10 nm to 400 nm), visible light (400 nm to 700 nm), infrared radiation (700 nm to 1 mm), and microwave radiation (1 mm to 30 em).
  • radiosensitizers activated by electromagnetic radiation, e.g., X-rays.
  • X-ray-activated radiosensitizers include, but are not limited to, the following: metronidazole, misonidazole, desmethylmisonidazole, pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, E09, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), bromodeoxycytidine, fluorodeoxyuridine (FUdR), hydroxyurea, cis-platin, and therapeutically effective analogs and derivatives of the same.
  • metronidazole misonidazole
  • desmethylmisonidazole pimonidazole
  • etanidazole nimorazole
  • mitomycin C RSU 1069
  • Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator of the sensitizing agent.
  • photodynamic radiosensitizers include the following, but are not limited to: hematoporphyrin derivatives, PHOTOFRI riD, benzoporphyrin derivatives, NPe6, tin etioporphyrin (SnET2), pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and derivatives of the same.
  • Radiosensitizers can be administered in conjunction with a therapeutically effective amount of one or more compounds in addition to a present carbazole compound, such compounds including, but not limited to, compounds that promote the incorporation of radiosensitizers to the target cells, compounds that control the flow of therapeutics, nutrients, and/or oxygen to the target cells, chemotherapeutic agents that act on the tumor with or without additional radiation, or other therapeutically effective compounds for treating cancer or other disease.
  • radiosensitizers examples include, but are not limited to, 5-fluorouracil (5-FU), leucovorin, oxygen, carbogen, red cell transfusions, perfluorocarbons (e.g., FLUOSOLW®-DA), 2,3-DPG, BW12C, calcium channel blockers, pentoxifylline, antiangiogenesis compounds, hydralazine, and L-BSO.
  • 5-fluorouracil 5-FU
  • leucovorin oxygen
  • carbogen red cell transfusions
  • perfluorocarbons e.g., FLUOSOLW®-DA
  • 2,3-DPG 2,3-DPG
  • BW12C calcium channel blockers
  • pentoxifylline e.g., antiangiogenesis compounds
  • hydralazine hydralazine
  • L-BSO L-BSO
  • the chemotherapeutic agent can be any pharmacological agent or compound that induces apoptosis.
  • the pharmacological agent or compound can be, for example, a small organic molecule, peptide, polypeptide, nucleic acid, or antibody.
  • Chemotherapeutic agents that can be used include, but are not limited to, alkylating agents, antimetabolites, hormones and antagonists thereof, natural products and their derivatives, radioisotopes, antibodies, as well as natural products, and combinations thereof.
  • a carbazole compound of the present disclosure can be administered with antibiotics, such as doxorubicin and other anthracycline analogs, nitrogen mustards, such as cyclophosphamide, pyrimidine analogs such as 5- fluorouracil, cis-platin, hydroxyurea, taxol and its natural and synthetic derivatives, and the like.
  • antibiotics such as doxorubicin and other anthracycline analogs
  • nitrogen mustards such as cyclophosphamide
  • pyrimidine analogs such as 5- fluorouracil, cis-platin, hydroxyurea, taxol and its natural and synthetic derivatives, and the like.
  • the compound in the case of mixed tumors, such as adenocarcinoma of the breast, where the tumors include gonadotropin-dependent and gonadotropin-independent cells, the compound can be administered in conjunction with leuprolide or goserelin (synthetic peptide analogs of LH-R
  • antineoplastic protocols include the use of an inhibitor compound with another treatment modality, e.g., surgery or radiation, also referred to herein as "adjunct anti-neoplastic modalities.”
  • Additional chemotherapeutic agents useful in the disclosure include hormones and antagonists thereof, radioisotopes, antibodies, natural products, and combinations thereof.
  • a compound having the structure (I) to (VI) of this disclosure can be provided in pharmaceutical compositions.
  • the pharmaceutical composition comprises one or more compounds having the structure (I) to (VI) of the present disclosure and a pharmaceutically acceptable carrier.
  • the kits of the disclosure can comprise one or more compounds of the structure (I) to (VI), alone, as pharmaceutical preparations, or separate pharmaceutical preparations with each pharmaceutical preparation comprising a separate compound having the structure (I) to (VI).
  • HPLC column Kinetex, 2.6 ⁇ , C I 8, 50 x 2.1 mm, maintained at 40 °C.
  • HPLC Gradient 1.0 mL/min, 95:5:0.1 water:acetonitrile:formic acid to 5:95:0.1 water:acetonitrile:formic acid in 2.0 min, maintaining for 0.5 min. Reported retention times are for method A unless indicated otherwise.
  • Analytical LC/MS method B was performed on a Shimadzu system with an attached API 165 single quadrupole mass spectrometer. Retention times were determined from the 220 nm chromatogram.
  • HPLC column Phenomenex, C I 8, 2.5 ⁇ , 20 x 2 mm, maintained at 25 °C.
  • HPLC Gradient 0.5 mL/min, 95:5:0.02 water:acetonitrile:CF 3 COOH to 5:95:0.02 water:acetonitrile:CF 3 COOH in 2.9 min, maintaining for 0.9 min.
  • Step 1 To a stirred solution of «-butyllithium (1.6 M in hexane, 8.78 mL, 14.05 mmol) under argon at -20°C was added 2,2,6,6-tetramethylpiperidine (2.37 mL, 14.05 mmol) in anhydrous tetrahydrofuran (15 mL). The mixture was cooled to -50 °C and a solution of 3- chlorobenzoic acid (1.0 g, 6.39 mmol) in anhydrous tetrahydrofuran (10 mL) was added dropwise. The mixture was stirred for 3 h.
  • Step 2 To a solution of 3-chloro-2-formylbenzoic acid (Preparation 2a-l, 1.35 g, 7.31 mmol) in water (13.5 mL) was added hydrazine hydrate (1.78 mL, 36.65 mmol), and the mixture was stirred at 95 °C for 4 h. The resulting precipitate was collected, washed with water (5 mL) and dried in air to give the title compound (545 mg, 3.01 mmol, 41%) as a white powder.
  • Step 1 A solution of 3-bromo-2-methoxybenzoic acid (3.0 g, 12.98 mmol) in thionyl chloride (15 mL) was stirred at 50 °C for 2 h and then evaporated. The residue was taken up in dichloromethane (50 mL) and to this solution was added methoxymethylamine hydrochloride ( 1.27 g, 13.0 mmol) and N,N-diisopropylethylamine (4.53 mL, 26.0 mmol). The mixture stirred at room temperature for 16 h. The reaction mixture was washed with water (2 x 20 mL) and the organic layer was dried over sodium sulfate and evaporated.
  • Step 2 3-Bromo-2,N-dimethoxy-N-methyl-benzarnide (Preparation 6a- 1 , 1.92 g, 7.0 mmol) was dissolved in tetrahydrofuran (6 mL). To this solution was added methylmagnesium bromide (3M in diethyl ether, 4.67 mL, 14.0 mmol) at 0 °C and the mixture stirred for 3 h. The reaction was quenched with saturated aqueous ammonium chloride (10 mL) and extracted with ethyl acetate (2 x 15 mL).
  • Step 1 To a suspension of 4-hydroxyindan-l -one (25.0 g, 169 mmol) in concentrated sulfuric acid (250 mL) at -25 °C was added slowly a mixture of fuming nitric acid (8.46 mL) and concentrated sulfuric acid (8.46 mL), maintaining the temperature between -25 °C and -10 °C during the addition. The reaction was monitored by TLC ( «-hexane:ethyl acetate, 4: 1 ) until complete conversion was achieved (25 min). The reaction mixture was poured onto crushed ice (ca. 1.5 kg) and the yellow precipitate collected by filtration.
  • Step 2 To a solution of 4-hydroxy-5-nitroindan-l -one (Preparation 8a-l, 5.0 g, 25.8 mmol) and triethylamine (3.97 mL, 28.5 mmol) in dichloromethane (50 mL) was added trifluoromethanesulfonic acid anhydride (4.57 mL, 27.2 mmol) dropwise at 0 °C. The mixture was stirred at room temperature for 1 h and washed with water (50 mL), 10% aqueous sodium carbonate (2 x 50 mL) and brine (25 mL). The organic layer was dried over sodium sulfate and evaporated.
  • Step 1 To a suspension of l-(4-aminophenyl)-ethanone (14.7 g, 109 mmol) in toluene (150 mL) at 40 °C was added N-bromosuccinimide (19.4 g, 109 mmol) in several portions over 30 min. After the addition was complete, the mixture was stirred at 40 °C for 15 min. Water (30 mL) was added and the organic layer was separated, washed with water (3 x 30 mL), dried over magnesium sulfate and evaporated to give the title compound (16.5 g, 77 mmol, 71%) as a brown crystalline solid. The crude product was used without further purification. LCMS: 97%, Rt 1.188 min, ESMS m/z 214 (M+H) + .
  • Step 2 To a stirred mixture of l-(4-amino-3-bromophenyl)-ethanone (Preparation 9a- 1 , 33 g, 154 mmol) in 20% aqueous tetrafluoroboric acid (143 mL) at 0 °C was added sodium nitrite (4M aqueous solution, 60 mL, 240 mmol) over 15 min. The mixture was stirred at 0 °C for 30 min. The resulting yellow foamy suspension was added to a vigorously stirring mixture of copper powder (53 g, 0.83 mol) and sodium nitrite (143 g, 2.07 mol) in water (286 mL) at room temperature.
  • sodium nitrite 4M aqueous solution, 60 mL, 240 mmol
  • Step 1 A biphasic mixture of 4-bromo-l-indanone (1.0 g, 4.74 mmol), 2- nitrophenylboronic acid (1.60 g, 9.48 mmol), l,l'-6/,s(diphenylphosphino)ferrocene palladium(II) dichloride (173 mg, 0.24 mmol) and potassium carbonate (1.31 g, 9.48 mmol) in l ,4-dioxane:water (4: 1, 32 mL) was heated at 120 °C for 80 min under microwave irradiation.
  • Step 2 A mixture of 4-(2-nitrophenyl)-indan-l -one (Preparation lOa-1, 870 mg, 3.44 mmol) and triphenylphosphine (2.25 g, 8.60 mmol) in chlorobenzene (14 mL) was heated at 200 °C for 60 min under microwave irradiation.
  • Step 1 A mixture of 2-bromo-l -fluoro-3-nitrobenzene (610 mg, 2.77 mmol), 4- (4,4,5,5-tetramethyl-[ l,3,2]dioxaborolan-2-yl)-indan-l-one (Preparation 7-1, 858 mg, 3.33 mmol), potassium carbonate (2M aq.
  • Step 2 A mixture of 4-(2-fluoro-6-nitrophenyl)-indan-l-one (Preparation l la-1, 450 mg, 1.65 mmol) and triphenylphosphine (1.08 g, 4.15 mmol) in chlorobenzene (4.5 mL) was irradiated at 200 °C in a microwave reactor for 1 h. The mixture was cooled to room temperature and the precipitate collected by filtration to afford the title compound (376 mg, 1.37 mmol, 67%) as an off-white powder.
  • LCMS 100%, Rt 1.516 min, ESMS m/z 240 (M+H) + .
  • Step 1 A mixture of trifluoromethanesulfonic acid 5-nitro-l-oxoindan-4-yl ester (Preparation 8-1, 1.5 g, 4.61 mmol), 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-indan-l- one (Preparation 7-1, 1.49 g, 5.77 mmol), 2 M aqueous potassium carbonate (4.6 mL) and 1,1 '- 0/s(diphenylphosphino)ferrocene palladium(II) dichloride (169 mg, 0.23 mmol) in 1,4-dioxane (38 mL) was stirred at 100 °C for 1 h in a sealed vial.
  • Step 2 A mixture of S-nitro ⁇ ' ⁇ '-tetrahydro- ⁇ 'Jftw-indenyl-l . l'-dione (Preparation 12a-l , 630 mg, 2.05 mmol) and triphenylphosphine (1.34 g, 5.13 mmol) in chlorobenzene (8.2 mL) was irradiated in a microwave reactor at 200 °C for 2 h. The mixture was cooled to room temperature and the precipitate collected.
  • Step 1 A mixture of 9-acetyl-l ,2-dihydro-6H-cyclopenta[c]carbazol-3-one (Preparation 13-1, 500 mg, 1.90 mmol), 1,3-dibromopropane (1.95 mL, 19.0 mmol) and cesium carbonate (2.47 g, 7.60 mmol) in N,N-dimethylformamide (25 mL) was stirred at 50 °C for 1 h. The mixture was poured into water (125 mL) and the precipitate collected.
  • Step 2 A mixture of 9-acetyl-6-(3-bromo-propyl)-l,2-dihydro-6H- cyclopenta[c]carbazol-3-one (Compound 2a- 1, 100 mg, 0.26 mmol), cyclopropylamine (55 ⁇ , 0.78 mmol) and cesium carbonate (338 mg, 1.04 mmol) in N,N-dimethylformamide (2 mL) was stirred at 50 °C for 72 h. The mixture was poured into water (10 mL) and the precipitate collected. The crude material was purified by column chromatography eluting with chloroform-.methanol (95:5) to afford the title compound as the free base.
  • Step 1 A mixture of 9-acetyl-l ,2-dihydro-6H-cyclopenta[c]carbazol-3-one (Preparation 13-1 , 281 mg, 1.07 mmol), methanesulfonic acid 2-(ter/-butoxycarbonyl-methyl- amino)-ethyl ester (541 mg, 2.13 mmol) and cesium carbonate (1.39 g, 4.28 mmol) in N,N- dimethylformamide (3 mL) was stirred at 50 °C for 16 h and then at 80 °C for 5 h.
  • Step 1 A mixture of 9-acetyl-l,2-dihydro-6H-cyclopenta[c]carbazol-3-one (Preparation 13-1, 1.70 g, 6.46 mmol), 2-bromo-l,l-diethoxyethane (2.65 mL, 19.4 mmol) and cesium carbonate (6.31 g, 19.4 mmol) in NN-dimethylformamide (17 mL) was stirred at 80 °C for 2 h. An additional portion of 2-bromo-l,l-diethoxyethane (2.65 mL, 19.4 mmol) was added and the reaction was stirred at 80 °C for 2 h and poured into water (85 mL).
  • Step 2 A solution of 9-acetyl-6-(2,2-diethoxyethyl)-l ,2-dihydro-6H- cyclopenta[c]carbazol-3-one (Compound 6a- 1, 1.20 g, 3.16 mmol) in trifluoroacetic acid (1 1.3 mL) was stirred at room temperature for 1 h. The mixture was evaporated and the residue triturated with water (10 mL). The solid was washed with water (1 x 10 mL) and diethyl ether (1 x 10 mL) to give the title compound (0.75 g, 2.46 mmol, 78%) as an off-white powder.
  • LCMS inconclusive; hydrate, hemiacetal and aldehyde masses detected, TLC: OK.
  • Step 3 A mixture of (9-acetyl-3-oxo-2,3-dihydro-l H-cyclopenta[c]carbazol-6- yl)-acetaldehyde (Compound 6b-l, 100 mg, 0.33 mmol) and piperidine (28 mg, 0.33 mmol) in dichloromethane (2 mL) was stirred at room temperature for 10 min. The mixture was then cooled to 0 °C and sodium triacetoxyborohydride (279 mg, 1.32 mmol) was added. The mixture was stirred at 0 °C for 1 h and room temperature for 2 h.
  • the reaction mixture was poured into water (15 mL) and extracted with dichloromethane (3 x 15 mL). The combined organic layers were washed with brine (15 mL), dried over magnesium sulfate and evaporated. The residue was purified by column chromatography eluting with dichloromethane.methanol (100:0- 95:5). The product was triturated with diethyl ether (ca. 1 mL) to afford the title compound (26 mg, 0.07 mmol, 21%) as a white powder.
  • PLX compounds were assessed for anti-fungal activity against a Candida albicans strain obtained from ATCC. Assays were carried out according to the protocol provided by the
  • Percentage reductions of cells compared to DMSO control were calculated after subtraction of background (broth without cells) for each compound. Experiments were performed in quadruplicate and repeated at least twice. Compounds that showed >50% average growth inhibition against C.albicans were chosen for secondary screening.
  • This example shows a table of the compounds of the present disclosure and their activity towards three different fungal species (i.e., C. albicans, C. glabrata, and A. fumigat s (48 h incubation)) using the method described in Example 20.
  • the MIC for 95% inhibition of growth is divided into 4 categories: A ⁇ 5 ⁇ , B 5-10 ⁇ , C > 10 ⁇ , D ⁇ 40% growth inhibition at 20 ⁇ .
  • This example shows a table of the compounds of the present disclosure and their activity towards the cell lines described in Example 22.
  • the LC50 for inhibition of growth is divided into 4 categories: A ⁇ 1 ⁇ , B 1 -5 ⁇ , C 5-20 ⁇ , D >20 ⁇ .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés carbazole de formule (I) qui peuvent être utilisés pour traiter des infections microbiennes, en particulier des infections fongiques, et pour tuer sélectivement des cellules cancéreuses.
PCT/RU2013/000866 2013-10-02 2013-10-02 Composés carbazole et leurs méthodes d'utilisation WO2015050471A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/RU2013/000866 WO2015050471A1 (fr) 2013-10-02 2013-10-02 Composés carbazole et leurs méthodes d'utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2013/000866 WO2015050471A1 (fr) 2013-10-02 2013-10-02 Composés carbazole et leurs méthodes d'utilisation

Publications (1)

Publication Number Publication Date
WO2015050471A1 true WO2015050471A1 (fr) 2015-04-09

Family

ID=52778966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2013/000866 WO2015050471A1 (fr) 2013-10-02 2013-10-02 Composés carbazole et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2015050471A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106565625A (zh) * 2016-11-04 2017-04-19 杭州励德生物科技有限公司 一种抗血小板减少症新药Lusutrombopag中间体的制备方法
JP2021527125A (ja) * 2018-06-07 2021-10-11 ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｓａｒｍ１阻害剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042445A1 (fr) * 2008-10-06 2010-04-15 Cleveland Biolabs, Inc. Composés carbazole et utilisations thérapeutiques desdits composés
RU2474612C2 (ru) * 2008-05-20 2013-02-10 Инкурон ЛЛК Индуцирование гибели клеток путем ингибирования адаптивного теплового шокового ответа

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2474612C2 (ru) * 2008-05-20 2013-02-10 Инкурон ЛЛК Индуцирование гибели клеток путем ингибирования адаптивного теплового шокового ответа
WO2010042445A1 (fr) * 2008-10-06 2010-04-15 Cleveland Biolabs, Inc. Composés carbazole et utilisations thérapeutiques desdits composés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS 1988, accession no. 11960-34-0 *
KATRITZKY, ALAN R. ET AL.: "Carbon-13 NMR chemical shift assignments for some carbazole derivatives''.", MAGNETIC RESONANCE IN CHEMISTRY, vol. 26, no. 4, 1988, pages 347 - 350 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106565625A (zh) * 2016-11-04 2017-04-19 杭州励德生物科技有限公司 一种抗血小板减少症新药Lusutrombopag中间体的制备方法
JP2021527125A (ja) * 2018-06-07 2021-10-11 ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｓａｒｍ１阻害剤

Similar Documents

Publication Publication Date Title
AU2019250170B2 (en) Benzamide and nicotinamide compounds and methods of using same
KR102325247B1 (ko) 치환된 벤조퓨라닐 및 벤즈옥사졸릴 화합물 및 이의 용도
WO2015020553A1 (fr) Composés carbazole et leurs méthodes d'utilisation
CN105492008B (zh) 用于抑制fasn的化合物及组合物
AU2009302546B2 (en) Carbazole compounds and therapeutic uses of the compounds
JP2005521698A (ja) 新規な三環式化合物
WO2014085607A1 (fr) Composés 2,3-dihydrobenzofuranyle substitués et leurs utilisations
CN108026067A (zh) 作为cot调节剂的6-氨基-喹啉-3-腈
CN113966324A (zh) Notch信号传导途径抑制剂及其在癌症治疗的用途
BR112014025416B1 (pt) agentes antimaláricos, composição farmacêutica compreendendo-os e uso dos mesmos
CN103402995A (zh) 新型吲哚、吲唑衍生物或其盐
CN110003204B (zh) 一种bet蛋白抑制剂、其制备方法及用途
CN107056789B (zh) 具有取代吡嗪并咪唑类衍生物,其制备及其在医药上的应用
WO2015050471A1 (fr) Composés carbazole et leurs méthodes d'utilisation
WO2015050472A1 (fr) Composés indole fusionnés et leurs méthodes d'utilisation
CN106810553B (zh) 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
KR20240014034A (ko) 헤테로비시클릭 화합물 및 그를 포함하는 약제학적조성물
WO2022022630A1 (fr) Dérivé oxa-azaspiro, son procédé de préparation et son utilisation pharmaceutique
CN115960082A (zh) 一种四取代的烯烃化合物、其制备方法及其在医药上的应用
CN116685323A (zh) 嘌呤酮衍生物、其制备方法及其在医药上的应用
US20160368872A1 (en) Compounds and methods for treating cancers
NZ715195B2 (en) Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13894973

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13894973

Country of ref document: EP

Kind code of ref document: A1